Clinical Trials Browser

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03399448 2023-06-22

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Phase 1 Terminated

3 enrolled

DermatologicPlasma cellSarcoma

Melanoma, Multiple Myeloma, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT05513612 2023-03-01

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Phase 1 Withdrawn

LymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04706936 2023-02-06

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Phase 1 Unknown

25 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03168438 2022-01-11

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Phase 1 Terminated

6 enrolled 19 charts

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT02660281 2021-11-03

HaploOnly

Phase 1 Completed

74 enrolled

LymphoidMyeloidPlasma cell

Hematologic Diseases, Lymphoma, Multiple Myeloma, Primary Myelofibrosis

NCT03018223 2021-09-16

Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT

Phase 1 Completed

32 enrolled 12 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT03958656 2021-09-09

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

Phase 1 Completed

13 enrolled 15 charts

Plasma cell

Multiple Myeloma

NCT03716856 2020-10-08

Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

Phase 1 Unknown

11 enrolled

Plasma cell

Multiple Myeloma

NCT02215967 2019-10-08

Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma

Phase 1 Completed

30 enrolled 13 charts

Plasma cell

Multiple Myeloma

NCT01342289 2018-10-17

Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

Phase 1 Completed

127 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT00909948 2018-03-29

RLI

Phase 1 Terminated

7 enrolled

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT00513474 2017-05-25

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Phase 1 Completed

46 enrolled 11 charts

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Blast Crisis, Burkitt Lymphoma, Graft vs Host Disease, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloproliferative Disorders, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02457650 2016-08-03

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Phase 1 Unknown

36 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT00089453 2012-04-19

Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

Phase 1 Completed

10 enrolled

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Clinical Trials

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

FT576 in Subjects With Multiple Myeloma

UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

CART-38 in Adult AML and MM Patients

Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma

FluBuATG

A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

IMMUNICY-1

KarMMa-4

VICTORY

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

HaploOnly

Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma

Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

RLI

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant